Atlanta, GANCT05327699Now EnrollingIRB Ready

Major Depressive Disorder Clinical Trial in Atlanta, GA

Access cutting-edge major depressive disorder treatment through this early phase 1 clinical trial at a research site in Atlanta. Study-provided care at no cost to qualified participants.

Sponsored by Emory University

Quick Self-Assessment

See if you qualify for this Atlanta location

Preparing your pre-screening questions…

Expert Care in Atlanta

Access major depressive disorder specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related major depressive disorder treatment provided free

Apply for This Atlanta Location

Check if you qualify for this major depressive disorder clinical trial in Atlanta, GA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Atlanta

    Convenient for GA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Atlanta site if eligible
  4. 4Begin participation

About This Major Depressive Disorder Study in Atlanta

The main purpose of this study is to investigate the effects of ketamine on decision-making and emotion processing in a sample of individuals diagnosed with Major Depressive Disorder (MDD).

Sponsor: Emory University

Who Can Participate

Inclusion Criteria

MDD Patients:
willing and able to give written informed consent
men or women, 18-65 years of age
primary diagnosis of DSM-V MDD, current, as diagnosed by the SCID-I
score of ≥20 on the Beck Depression Inventory, which will include patients characterized as having "moderate/severe" (20-28) or "very-severe" (29-63) depressive symptoms
off all antidepressant therapy for at least 8 weeks prior to the baseline visit Healthy Controls:
willing and able to give written informed consent
men or women, 18-65 years of age

Exclusion Criteria

MDD Patients:
history of any bipolar disorder or psychotic disorder
active psychotic symptoms of any type
substance abuse/dependence within 6 months of study entry (as determined by SCID)
unstable cardiovascular, endocrinologic, hematologic, hepatic, renal, or neurologic disease (as determined by physical examination and laboratory testing), including upper respiratory disease or asthma, glaucoma or porphyria.
active suicidal ideation as determined by a score ≥3 on the Columbia Suicide Severity Rating Scale (C-SSR)
use of any recreational drugs as confirmed by urine drug screen at the time of scanning
pregnancy or lactation
use of glucocorticoids at any time during the study
Raynaud's disease that may interfere with the cold-pressor
contraindications for MRI
MMSE score \<28
elevated blood pressure prior to infusion (systolic \> 160 or diastolic \>100)
history of treatment resistance as determined by ATRQ
prior adverse reaction to ketamine
use of antipsychotic medications
use of greater than 2mg daily of lorazepam or similar benzodiazipine.
Regular smoker as self-reported Healthy Controls:
evidence of any psychiatric disorder with exception of specific phobia, and no history of any psychiatric disorder except mild past substance use disorder as diagnosed by the SCID-I
history of any substance abuse within the last 6 months
use of any recreational drugs as confirmed by urine drug screen at the time of scanning
pregnancy or lactation
use of glucocorticoids at any time during the study
Raynaud's disease that may interfere with the cold-pressor
contraindications for MRI
MMSE score \<28
Regular smoker as self-reported

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Atlanta?

Yes, this clinical trial (NCT05327699) has an active research site in Atlanta, GA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Major Depressive Disorder Treatment Options in Atlanta, GA

If you're searching for major depressive disorder treatment options in Atlanta, GA, this clinical trial (NCT05327699) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Atlanta research site is actively enrolling participants for this early phase 1 clinical trial. You'll receive care from experienced major depressive disorder specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all major depressive disorder clinical trials near you to find additional studies recruiting in your area.

More Depression Trials in Atlanta, GA

See all depression clinical trials recruiting in Atlanta — not just this study.

Browse Depression Trials in Atlanta →

Browse More Trials by Condition

Depression TrialsMajor Depressive Disorder TrialsAll Conditions →

Ready to Join in Atlanta?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Atlanta, GA